ST. LOUIS, MO and SAN DIEGO, CA, Feb. 26, 2025 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the appointment of Jim Faulkner, Ph.D., as chief technology officer, initially serving on an interim basis. “Jim brings a specialized skill set...
